Acute Respiratory Distress Syndrome News and Research RSS Feed - Acute Respiratory Distress Syndrome News and Research

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. [More]
The Lancet publishes new Seminar on MERS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security. [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
New study describes way to regenerate lung tissue after injury

New study describes way to regenerate lung tissue after injury

A new collaborative study describes a way that lung tissue can regenerate after injury. The team found that lung tissue has more dexterity in repairing tissue than once thought. [More]
Rare genetic mutation explains why flu can kill in rare cases

Rare genetic mutation explains why flu can kill in rare cases

Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation. [More]
Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition that affects approximately 200,000 people a year in the United States and has a higher mortality rate than breast and prostate cancer combined. The condition most often occurs in people who are critically ill or who have significant injuries; those who do survive it often experience profound skeletal muscle weakness. [More]
Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Among patients with severe community-acquired pneumonia and high initial inflammatory response, the use of the corticosteroid methylprednisolone decreased treatment failure, compared with placebo, according to a study in the February 17 issue of JAMA. [More]
Balanced blood product ratios can improve outcomes in severe trauma patients

Balanced blood product ratios can improve outcomes in severe trauma patients

Among patients with severe trauma and major bleeding, those who received a transfusion of a balanced ratio of plasma, platelets, and red blood cells (RBCs) were more likely to have their bleeding stopped and less likely to die due to loss of blood by 24 hours compared to patients who received a transfusion with a higher ratio of RBCs, according to a study in the February 3 issue of JAMA. [More]
UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, and Jeffrey A. Rivest, MS, President and Chief Executive Officer of University of Maryland Medical Center (UMMC), today announced the official launch of a new "Program in Lung Healing," that will further the School's position as a national leader in research, education and clinical innovation for acute ailments of the lung and respiratory system. [More]
Patients who receive lungs from heavy drinkers more likely to develop severe primary graft dysfunction

Patients who receive lungs from heavy drinkers more likely to develop severe primary graft dysfunction

Lung transplant patients who receive lungs from heavy drinkers are nearly nine times more likely to experience a life-threatening complication called primary graft dysfunction, a Loyola University Medical Center study has found. [More]
Better physical functioning associated with remission of general anxiety, PTSD symptoms

Better physical functioning associated with remission of general anxiety, PTSD symptoms

In a two-year longitudinal study involving 13 intensive care units in four U.S. hospitals, researchers found that better physical functioning — basic and complex activities considered essential for maintaining independence — is associated with remission of general anxiety and post-traumatic stress disorder (PTSD) symptoms. These findings may help clinicians be better prepared for caring for the growing number of survivors of critical illness, potentially leading to a better quality of recovery for patients. [More]
Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Critical care is defined by life-threatening conditions, which require close evaluation, monitoring, and treatment by appropriately trained health professionals. Cardiovascular care bears these same requirements. [More]
CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany. [More]
Study reveals how stem cells work to improve lung function in ARDS

Study reveals how stem cells work to improve lung function in ARDS

A new study has revealed how stem cells work to improve lung function in acute respiratory distress syndrome (ARDS). [More]
Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinking damages the body in many ways. In addition to liver failure, alcoholics are at a much greater risk of developing pneumonia and life threatening acute respiratory distress syndrome (ARDS), for which there is no treatment. [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
New tool can help doctors identify patients at highest risk for respiratory failure after surgery

New tool can help doctors identify patients at highest risk for respiratory failure after surgery

A new prediction tool can help doctors better identify patients who are at highest risk for respiratory failure after surgery and therefore prevent the often deadly condition, suggest data from a large multi-center study published in the May issue of Anesthesiology. [More]
Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Acute respiratory distress syndrome is a leading cause of respiratory failure after surgery. Patients who develop the lung disorder postoperatively are at higher risk of dying in the hospital, and those who survive the syndrome may still bear its physical effects years later. [More]
Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. [More]
Advertisement
Advertisement